Therefore, a peptide named PB1‐p62 was designed to target PBRM1 and p62, resulting in the degradation of most of PBRM1 via autophagy and notably ensuring the efficacy of immunotherapy for renal cancer. This evidence concerns the gene SQSTM1 and renal carcinoma.